Evidence map›Paper›PMID 40213466›Full record

ArticleSmall science2024

Renal Clearable H-Dots Leveraging Ligand Complexation for Enhanced Active Tumor Targeting.

Yanan Cui, Seung Hun Park, Wesley R Stiles, Atsushi Yamashita, Jason Dinh, Richard S Kim, Yadong Zhang, Xiaoran Yin, Yoonji Baek, Haoran Wang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yanan CuiGordon Center for Medical Imaging Department of Radiology Massachusetts General Hospital and Harvard Medical School Boston MA 02114 USA.
Seung Hun ParkGordon Center for Medical Imaging Department of Radiology Massachusetts General Hospital and Harvard Medical School Boston MA 02114 USA.
Wesley R StilesGordon Center for Medical Imaging Department of Radiology Massachusetts General Hospital and Harvard Medical School Boston MA 02114 USA.
Atsushi YamashitaGordon Center for Medical Imaging Department of Radiology Massachusetts General Hospital and Harvard Medical School Boston MA 02114 USA.
Jason DinhGordon Center for Medical Imaging Department of Radiology Massachusetts General Hospital and Harvard Medical School Boston MA 02114 USA.
Richard S KimGordon Center for Medical Imaging Department of Radiology Massachusetts General Hospital and Harvard Medical School Boston MA 02114 USA.
Yadong ZhangSchool of Pharmacy Shandong First Medical University & Shandong Academy of Medical Sciences Jinan Shandong 250021 China.
Xiaoran YinGordon Center for Medical Imaging Department of Radiology Massachusetts General Hospital and Harvard Medical School Boston MA 02114 USA.
Yoonji BaekGordon Center for Medical Imaging Department of Radiology Massachusetts General Hospital and Harvard Medical School Boston MA 02114 USA.
Haoran WangGordon Center for Medical Imaging Department of Radiology Massachusetts General Hospital and Harvard Medical School Boston MA 02114 USA.
Kai BaoGordon Center for Medical Imaging Department of Radiology Massachusetts General Hospital and Harvard Medical School Boston MA 02114 USA.
Homan KangGordon Center for Medical Imaging Department of Radiology Massachusetts General Hospital and Harvard Medical School Boston MA 02114 USA.ORCID https://orcid.org/0000-0002-0732-9779
Hak Soo ChoiGordon Center for Medical Imaging Department of Radiology Massachusetts General Hospital and Harvard Medical School Boston MA 02114 USA.ORCID https://orcid.org/0000-0002-7982-6483

Funding

Long-Acting, Short-Residing Nanochelators for Iron Overload TherapyR01HL163273 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI CHOI, HAK SOO, KIM, JONGHAN · 2023 to 2025
$2.2M
NHLBI NIH HHS R01 HL163273
6 · The paper itself

Abstract

The use of ligand conjugation onto nanoparticle surfaces as an active targeting strategy has gained significant attention in the pursuit of improving tumor-specific delivery and retention. However, the chemical conjugation of targeting moieties often induces alterations in the physicochemical properties of nanoparticles, including size, conformation, charge-to-mass ratio, and hydrophilicity/lipophilicity, resulting in unexpected biodistribution and pharmacokinetic profiles. Here, the enhanced active targeting efficiency achieved by integrating cyclic arginine-glycine-aspartic acid (cRGD) peptides onto ultrasmall nanocarrier H-dot while preserving its essential physicochemical and pharmacokinetic attributes is investigated. The resulting cRGD/H-dots demonstrate improved cellular uptake via integrin α

Indexed as

active targetingcyclic arginine–glycine–aspartic acidsnanoparticlespassive targetingtumor targeting

Identifiers

PMID40213466
PMCPMC11935198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.